These results suggest that decreased activity of the CHK1 pathway may be important for the synergistic anti-tumor activities of the combination of panobinostat and etoposide, doxorubicin or cisplatin in high-risk neuroblastoma cell lines. The gene discussed is CHEK1; the disease is neoplasm.